SCMP Profile
Sucampo Pharmaceuticals, Inc. (SCMP) was a biopharmaceutical company focused on developing and commercializing therapies to treat gastrointestinal, ophthalmic, and oncology-related disorders. The company was headquartered in Rockville, Maryland, and was founded in 1996.
SCMP’s lead product, Amitiza, was approved by the US Food and Drug Administration (FDA) for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults. The company also had a number of other product candidates in development, including cobiprostone for the prevention of oral mucositis in cancer patients, and a variety of other compounds in early-stage development.
In December 2017, SCMP was acquired by Mallinckrodt Pharmaceuticals for $1.2 billion. The acquisition was intended to expand Mallinckrodt’s specialty pharmaceutical portfolio and strengthen its presence in the gastrointestinal and ophthalmic therapeutic areas.
Prior to the acquisition, SCMP had reported strong financial results, with increasing revenue and earnings over the previous several years. However, the company had also faced challenges related to the commercialization of its products, particularly in international markets.
Overall, SCMP was a company with a strong focus on developing and commercializing novel therapies to address important medical needs. Its acquisition by Mallinckrodt Pharmaceuticals provided a pathway for continued growth and expansion in the biopharmaceutical industry.
|
